## **Pharmacophore**

ISSN-2229-5402



Journal home page: http://www.pharmacophorejournal.com

# PREVALENCE OF RISKY BEHAVIORS AMONG PATIENTS ATTENDING DIABETES AND ENDOCRINOLOGY CLINICS IN KFAFH 2022

## Ahmed Abdulbasit Baharith<sup>1\*</sup>, Osama Naser Alharbi<sup>2</sup>

1. Consultant of Family Medicine, Ministry of Health, Jeddah, Saudi Arabia.

2. Senior Registrar of Family Medicine, Ministry of Health, Jeddah, Saudi Arabia.

#### ARTICLE INFO

Received: 02 Dec 2022 Received in revised form: 17 Feb 2023 Accepted: 18 Feb 2023 Available online: 28 Feb 2023

*Keywords:* Endocrinology, Diabetes mellitus, Diabetes complications, Diabetes mellitus type 2, Diabetic angiopathies

## ABSTRACT

As a major killer, diabetes places a significant financial strain on healthcare systems across the globe. This research aims to determine the prevalence of smoking and physical inactivity among diabetics attending Diabetes Clinics in King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia. We used a cross-sectional study design. Data was collected during the clinical appointments at the Diabetes and Endocrinology clinics. All diabetic patients attending the Diabetes and Endocrinology clinics. All diabetic patients attending the Diabetes and Endocrinology clinics. All diabetic patients attending the Diabetes and Endocrinology clinics in KFAFH, aged 18 and above. Using the Raosoft calculator, the sample size was 243 diabetic patients. The sampling technique is non-probability convenient sampling. The study included 100 participants. The mean age of study participants was  $50.07 \pm 18.8$  years. Age ranged from 16 to 90 years. There were 66 male participants and 34 female participants. Type of diabetes was statistical significance with regular exercise, especially among type 2 diabetes patients (P= 0.041). The use of insulin was statistical significance with blood glucose monitoring (P= 0.004). Male participants were smokers than others (P= 0.042). Patients with a family history of diabetes were more smokers than others (P= 0.042). Patients with a family history of diabetes with regard to their diabetes condition. Lack of exercise, smoking, less frequent blood glucose monitoring and not following up with a dictician were the most risky behaviors. This is reflected by the high prevalence of diabetes complications among study participants.

This is an **open-access** article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**To Cite This Article:** Baharith AA, Alharbi ON. Prevalence of Risky Behaviors among Patients Attending Diabetes and Endocrinology Clinics in KFAFH 2022. Pharmacophore. 2023;14(1):100-10. https://doi.org/10.51847/hK2KhX09na

#### Introduction

Worldwide, type 2 diabetes is a common health concern [1, 2]. The numerous microvascular (retinopathy, nephropathy, and peripheral neuropathy) and macrovascular (Transient ischemic attacks, stroke, myocardial infarction, and peripheral arterial disease) microvascular and macrovascular (Transient ischemic attacks, stroke, myocardial infarction, and peripheral arterial disease) complications it can cause are hallmarks of this disease [3]. Tobacco use and a lack of physical activity are two important reasons for its prevalence.

It is considered that cardiovascular disease, cancer, stroke, and diabetes mellitus (DM) are the primary causes of mortality and disability on a global scale [4]. The vast majority of the worldwide burden of non-communicable diseases is related to fast socio-demographic and epidemiological trends driven by risky lifestyles in developing countries [5]. Both the development and progression of the disease may be linked back to preventable behavioral risk factors, such as a poor diet, lack of physical activity, smoking, and excessive alcohol use [6, 7].

Type 2 diabetes mellitus is one of the four most prevalent non-communicable diseases (NCDs) and is a metabolic disorder characterized by abnormally elevated blood glucose levels due to alterations in carbohydrate, lipid, and protein metabolism. The underlying causes of type 2 diabetes [7] include changes in insulin production, insulin action, or both. Type 1, type 2, and gestational diabetes are the three most common kinds of diabetes. Diabetes today affects 1 in 11 individuals globally; nevertheless, over half of the 451 million people living with the illness are ignorant of their condition, and 5% of all yearly deaths may be related to diabetes [8].

**Corresponding Author:** Ahmed Abdulbasit Baharith; Consultant of Family Medicine, Ministry of Health, Jeddah, Saudi Arabia. E-mail: Ahmed.baharith@yahoo.com

## Pharmacophore, 14(1) 2023, Pages 100-110

Consequently, diabetes has significant financial, social, and health repercussions, and this burden has increased and been considerably exacerbated in settings and countries with few resources [9]. In 2017, the globe spent \$850 billion on diabetes treatment as one example [8]. The region continues to hold a considerable proportion of the world's DM, placing a disproportionate strain on specific states [10].

Even though there is presently no cure for diabetes, it is possible to delay the development of symptoms and improve general health [11]. These may be the consequence of a mix of factors, including the fact that the emphasis has switched from treating illnesses to concentrating on the complete person and pursuing preventive measures. However, the outcomes are not even close to satisfactory [12]. Moreover, insufficient healthcare and weak prevention measures [13] aggravate poverty and early death in the country. Patients with diabetes whose clinical results are improved by active treatment and good lifestyle choices [11].

Moreover, even without additional cutting-edge technology and/or medications, the optimal levels of diabetes management objectives may be obtained [14]. Self-monitoring of blood glucose (SMBG), nutritional control, regular physical activity, medication adherence, and foot care by diabetes patients might all contribute [15].

Therefore, it may be able to obtain the desired outcomes in terms of diabetes management by engaging patients, offering comprehensive care, and establishing objectives from the viewpoint of the person with diabetes. For instance, maintaining a balanced blood sugar level is critical for treating diabetes and reducing the risk of significant complications, hospitalization, and mortality [16]. Instead of concentrating only on the health of the patient, diabetes therapy must take a more systemic approach [10]. Therefore, it is of the utmost importance to empower individuals to make effective decisions about their health and to become essential actors in their health, as opposed to just collecting and receiving their prescription refills [17]. This research aims to determine the prevalence of smoking and physical inactivity among diabetics attending Diabetes Clinics in King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.

#### **Materials and Methods**

#### Study Design

We used a cross-sectional study design. Data was collected during the clinical appointments at the Diabetes and Endocrinology clinics.

The data was collected by the researchers.

#### Eligibility Criteria

All diabetic patients attending the Diabetes and Endocrinology clinics in KFAFH, aged 18 and above.

#### Sample Size

Using the Raosoft calculator, the sample size was 243 diabetic patients. The sampling technique is non-probability convenient sampling.

#### Data Collection Tool

The data was collected by researchers during the clinic appointment. The clinical data collection is adopted from two validated questionnaires: The International Physical Inactivity Questionnaire IPAQ, and The Global Tobacco Surveillance System Questionnaire GTSSQ.

## The Data Collection Was Composed of Three Main Parts

- 1. Socio-demographic and personal characteristics including age, gender, educational level, occupation, and monthly income.
- 2. Medical characteristics include diabetes type, duration, medications, complications, smoking history, and other chronic conditions.
- 3. The third part will contain detailed information about smoking type, duration, and family history.

#### Data Analysis

This study was analyzed using IBM SPSS version 23 (IBM Corp., Armonk, N.Y., USA) and visually presented by using GraphPad Prism version 8 (GraphPad Software, Inc., San Diego, CA, USA). Simple descriptive statistics were used to define the characteristics of the study variables through the form of counts and percentages for the categorical and nominal variables while continuous variables are presented by mean and standard deviations. To establish a relationship between categorical variables, this study used a chi-square test. While comparing two group means and more than two groups, an independent *t*-test and One-way ANOVA Test respectively were used. These tests were done with the assumption of normal distribution. Lastly, a conventional p-value <0.05 was the criteria to reject the null hypothesis.

#### Ethical Consideration

A conditional approval was granted by the Research and Ethics Committee, King Fahd Armed Forces Hospital.

Pharmacophore, 14(1) 2023, Pages 100-110

## **Results and Discussion**

## Characteristics of the 100 Study Samples

The study included 100 participants. The mean age of study participants was  $50.07 \pm 18.8$  years. Age ranged from 16 to 90 years. There were 66 male participants and 34 female participants. The mean body mass index was 25.35 kg/m<sup>2</sup>, which indicates an overweight. Most of the study participants were married (n= 77, 77%). Most of the study participants had a bachelor's degree (n= 75). More than half of the study participants were employed (n= 56).

The mean duration of diabetes since diagnosis was  $13.47 \pm 9$  years. The most frequent type of diabetes was type 2 diabetes (n= 65). Most of the study participants were managed by insulin (n= 94). The most common diabetes complications observed was retinopathy, then nephropathy, then neuropathy, and the other complications are (sexual dysfunction, strke, diabetic foot, myocardial infarction, and gastroparesis).

Besides medications used to manage diabetes among study participants, they were prescribed other medications for concurrent conditions. The most commonly prescribed was Perindopril (n=59), and atorvastatin (n=43).

Most of the study participants had comorbid conditions besides diabetes. The most frequent comorbid conditions were hypertension (n= 63), dyslipidemia, and hypothyroidism. and this explains the most frequently prescribed medication which was antihypertensive treatment.

Some of the study participants practiced regular exercise (n=18). The majority of study participants check their blood glucose daily (n=94) and the same is used to follow up with a dietitian (n=93). Family history of diabetes was prevalent among 62 participants.

About the source of information among patients regarding diabetes: the most frequent sources were a physician, diabetes educator, friends, and social media. (arranged from the most frequent to the least frequent)

Most of the study participants are non-smokers (n=74). Results related to smoking status among study participants are presented in **Table 1**.

X7 • 11		<u> </u>	0/
Variables		Count	%
Total		100	100.0
	Non-smoker	74	74.0
Smoking status	Smoker	15	15.0
	Ex-smoker	11	11.0
Type of smoking	Cigarettes	15	100.0
Number cigarettes	Less than 10 per day	1	6.7
	10 -20 per day	6	40.0
	More than 20 per day	8	53.3
	0	14	58.3
	1	7	29.2
Number of smoking cessation attempts —	2	2	8.3
—	3	1	4.2
Seen a physician in the past year?	Yes	100	100.0
	Non-smoker	74	74.0
Ottered smoking cessation advice?	Yes	26	26.0

**Cable 1.** Risky behavior among study participants

Exercise practice was a good behavior prevalent among 21 participants. Results related to exercise practice among study participants are summarized in **Table 2**.

Table 2. Exerc	cise practice among study participan	ts	
Variables		Count	%
Total		100	100.0
Everyised in the past week?	No	79	79.0
Exercised in the past week?	Yes	21	21.0
		Count	%
Total		21	100.0
Minutes of evening non-weak	Less than 150	15	71.4
Minutes of exercise per week	More than 150	6	28.6

Baharith and Alharbi, 2023						
Pharmacophore, 14(1) 2023, Pages 100-110						
Minutes of evening non-day	Less than 150	20	95.2			
Minutes of exercise per day	More than 150	1	4.8			

## Statistically Significant Results

Participants' characteristics were tested for statistically significant relationships with regular exercise practice as illustrated in **Table 3**. Type of diabetes was statistical significance, especially among type 2 diabetes patients (P= 0.041).

Table 3. Statistical relationships between participants' characteristics and regular exercise

¥7	1	T-4-1	Regular	Regular exercise	
variao	nes	Total	No	Yes	p-value
Tota	Total		82(82.0%)	18(18.0%)	-
Age		100	$51.23 \pm 18.4$	$44.78\pm20.3$	0.188
Years since of	liagnosis	99	$13.39\pm8.8$	$13.85\pm10.2$	0.846
Conden	Male	66	51(77.3%)	15(22.7%)	0.096
Gender -	Female	34	31(91.2%)	3(8.8%)	0.080
Manital status	status <u>Single</u>	22	17(77.3%)	5(22.7%)	0.512
Marital status	Married at least once	78	65(83.3%)	13(16.7%)	0.515
	High school and below	25	21(84.0%)	(84.0%) 4(16.0%) (84.0%) 0.7	0.764
Educational level	Bachelor	75	61(81.3%)	14(18.7%)	0.764
	Employed	56	44(78.6%)	12(21.4%)	
	Housewife	9	8(88.9%)	1(11.1%)	0.664
Occupational status -	Student	9	7(77.8%)	2(22.2%)	0.664
-	Retired	26	23(88.5%)	3(11.5%)	
-	Underweight	3	3(100.0%)	0(0.0%)	
	Normal weight	45	33(73.3%)	12(26.7%)	0.010
BMI -	Overweight	42	37(88.1%)	5(11.9%)	0.218
-	Obese	10	9(90.0%)	1(10.0%)	
	Gestational diabetes	4	3(75.0%)	1(25.0%)	
-	Type 1	27	19(70.4%)	8(29.6%)	
Diabetes type	Type 2	65	58(89.2%)	7(10.8%)	0.041 <sup>a</sup>
-	LADA	3	1(33.3%)	2(66.7%)	
-	MODY	1	1(100.0%)	0(0.0%)	
	No	6	6(100.0%)	0(0.0%)	0.005
On Insulin? –	Yes	94	76(80.9%)	18(19.1%)	0.237
	No	36	26(72.2%)	10(27.8%)	
On oral hypoglycaemic agents? –	Yes	64	56(87.5%)	8(12.5%)	0.056
	No	22	20(90.9%)	2(9.1%)	
Compliant with medications? –	Yes	78	62(79.5%)	16(20.5%)	0.218
	No	33	26(78.8%)	7(21.2%)	
Existing DM complications? –	Yes	67	56(83.6%)	11(16.4%)	0.557
Comorbidities -	None	16	11(68.8%)	5(31.3%)	
	Yes	84	71(84.5%)	13(15.5%)	0.132
	No	38	29(76.3%)	9(23.7%)	
Family history of diabetes	Yes	62	53(85.5%)	9(14.5%)	0.247
	<sup>a</sup> -significant using Chi-Squ	are Test at <0.	.05 level.		

Participants' characteristics were tested for statistically significant relationships with blood glucose monitoring as illustrated in **Table 4**. The use of insulin was statistical significance (P=0.004).

Table 4. Statistical relationships between participants' characteristics and blood glucose monitoring

Variables	Total	Frequency of blood	n valua	
v arradies	Total	Daily	Weekly	p-value
Total	100	94(94.0%)	6(6.0%)	-
Age	100	$49.55\pm18.7$	$58.17 \pm 19.9$	0.278

	Baharith Pharmacophore	n and Alhar 2, 14(1) 2023,	bi, 2023 Pages 100-110		
Years sin	ce diagnosis	99	13.31 ± 9.0	$16.00\pm10.0$	0.482
<i>c</i> 1	Male	66	61(92.4%)	5(7.6%)	0.055
Gender –	Female	34	33(97.1%)	1(2.9%)	- 0.355
<b>.</b>	Single	22	21(95.5%)	1(4.5%)	0.745
Marital status –	Married at least once	78	73(93.6%)	5(6.4%)	- 0.745
	High school and below	25	24(96.0%)	1(4.0%)	0.627
Educational level –	Bachelor	75	70(93.3%)	5(6.7%)	- 0.627
	Employed	56	53(94.6%)	3(5.4%)	
	Housewife	9	8(88.9%)	1(11.1%)	0.7(2
Occupational status –	Student	9	9(100.0%)	0(0.0%)	- 0.762
-	Retired	26	24(92.3%)	2(7.7%)	-
	Underweight	3	3(100.0%)	0(0.0%)	
-	Normal weight	45	44(97.8%)	1(2.2%)	0.170
BMI -	Overweight	42	39(92.9%)	3(7.1%)	- 0.179
	Obese	10	8(80.0%)	2(20.0%)	-
	Gestational diabetes	4	4(100.0%)	0(0.0%)	
-	Type 1	27	26(96.3%)	1(3.7%)	-
Diabetes type	Type 2	65	60(92.3%)	5(7.7%)	0.895
-	LADA	3	3(100.0%)	0(0.0%)	-
-	MODY	1	1(100.0%)	0(0.0%)	-
On Inculin?	No	6	4(66.7%)	2(33.3%)	0.0048
On insum? –	Yes	94	90(95.7%)	4(4.3%)	- 0.004
On oral hypoglycaemic	No	36	35(97.2%)	1(2.8%)	0.200
agents?	Yes	64	59(92.2%)	5(7.8%)	- 0.309
Compliant with	No	22	20(90.9%)	2(9.1%)	0.490
medications?	Yes	78	74(94.9%)	4(5.1%)	- 0.489
Existing DM	No	33	32(97.0%)	1(3.0%)	0.290
complications?	Yes	67	62(92.5%)	5(7.5%)	- 0.380
Comorbidition	None	16	16(100.0%)	0(0.0%)	0.270
Comorbidities -	Yes	84	78(92.9%)	6(7.1%)	- 0.270
Family history of	No	38	36(94.7%)	2(5.3%)	0 808
diabetes	Yes	62	58(93.5%)	4(6.5%)	- 0.000
	<sup>a</sup> -significant using	Chi-Square T	est at <0.05 level.		

Participants' characteristics were tested for statistically significant relationships with dietician follow-up as illustrated in **Table 5**. However, none of the characteristics seemed to be statistically significant.

 Table 5. Statistical relationships between participants' characteristics and dietician follow up

X7	Variables		Seen a di			
var			No	Yes	p-value	
Т	otal	100	7(7.0%)	93(93.0%)	-	
ŀ	Age	100	$55.29 \pm 16.5$	$49.68 \pm 19.0$	0.449	
Years sine	ce diagnosis	99	$12.43\pm9.6$	$13.55\pm9.0$	0.754	
Condon	Male	66	6(9.1%)	60(90.9%)	0.254	
Gender	Female	34	1(2.9%)	33(97.1%)	0.234	
Monital status	Single	22	1(4.5%)	21(95.5%)	0,600	
Maritar status	Married at least once	78	6(7.7%)	72(92.3%)	0.009	
Educational laval	High school and below	25	3(12.0%)	22(88.0%)	0.258	
Educational level	Bachelor	75	4(5.3%)	71(94.7%)	0.238	
	Employed	56	4(7.1%)	52(92.9%)		
	Housewife	9	1(11.1%)	8(88.9%)	0.010	
Occupational status	Student	9	0(0.0%)	9(100.0%)	0.818	
	Retired	26	2(7.7%)	24(92.3%)		

	Pharmacophore, 1	and Alharbi, 14(1) 2023, Pa	2023 ges 100-110		
	Underweight	3	0(0.0%)	3(100.0%)	
	Normal weight	45	3(6.7%)	42(93.3%)	0.260
BIMI —	Overweight	42	2(4.8%)	40(95.2%)	0.309
	Obese	10	2(20.0%)	8(80.0%)	
	Gestational diabetes	4	0(0.0%)	4(100.0%)	
—	Type 1	27	1(3.7%)	26(96.3%)	
Diabetes type	Type 2	65	6(9.2%)	59(90.8%)	0.818
—	LADA	3	0(0.0%)	3(100.0%)	
—	MODY	1	0(0.0%)	1(100.0%)	
	No	6	1(16.7%)	5(83.3%)	0.229
On insum? —	Yes	94	6(6.4%)	88(93.6%)	0.558
On oral hypoglycaemic	No	36	1(2.8%)	35(97.2%)	0.215
agents?	Yes	64	6(9.4%)	58(90.6%)	0.215
Compliant with madiantiana?	No	22	2(9.1%)	20(90.9%)	0.662
Compliant with medications? —	Yes	78	5(6.4%)	73(93.6%)	0.005
Enistin - DMlisstin9	No	33	2(6.1%)	31(93.9%)	0.706
Existing DM complications? —	Yes	67	5(7.5%)	62(92.5%)	0.796
Comorbidition	None	16	1(6.3%)	15(93.8%)	0.000
Comorbidities —	Yes	84	6(7.1%)	78(92.9%)	0.090
Family history of diabetee	No	38	2(5.3%)	36(94.7%)	0.504
Family history of diabetes –	Yes	62	5(8.1%)	57(91.9%)	- 0.594

Participants' characteristics were tested for statistically significant relationships with smoking status as illustrated in **Table 6**. Male participants were smokers more than female participants (P= 0.003). Patients with current complications were more smokers than others (P= 0.042). Patients with a family history of diabetes were more smokers than others (P=0.016).

Table 6. Statistical relationships between participants' characteristics and smoking status

Vari	ablas	Total	Smoking status			n volno
vari	ables	Total	Non-smoker	Smoker	Ex-smoker	- p-value
To	otal	100	74(74.0%)	15(15.0%)	11(11.0%)	-
А	ge	100	$48.32 \pm 19.7$	$49.33 \pm 16.5$	$62.82\pm8.3$	0.056
Years sinc	e diagnosis	99	$13.58\pm9.6$	$10.87\pm6.2$	$16.27\pm8.4$	0.318
Condon	Male	66	42(63.6%)	15(22.7%)	9(13.6%)	0.0028
Gender	Female	34	32(94.1%)	0(0.0%)	2(5.9%)	- 0.003*
Manital status	Single	22	20(90.9%)	2(9.1%)	0(0.0%)	0.020
Marital status	Married at least once	78	54(69.2%)	13(16.7%)	11(14.1%)	- 0.089
Educational land	High school and below	25	21(84.0%)	2(8.0%)	2(8.0%)	0.404
Educational level	Bachelor	75	53(70.7%)	13(17.3%)	9(12.0%)	0.404
	Employed	56	39(69.6%)	12(21.4%)	5(8.9%)	- 0.062
	Housewife	9	9(100.0%)	0(0.0%)	0(0.0%)	
Occupational status	Student	9	7(77.8%)	2(22.2%)	0(0.0%)	
	Retired	26	19(73.1%)	1(3.8%)	6(23.1%)	_
	Underweight	3	3(100.0%)	0(0.0%)	0(0.0%)	
DN	Normal weight	45	34(75.6%)	8(17.8%)	3(6.7%)	- 0.750
BMI	Overweight	42	30(71.4%)	6(14.3%)	6(14.3%)	- 0.750
	Obese	10	7(70.0%)	1(10.0%)	2(20.0%)	-
	Gestational diabetes	4	4(100.0%)	0(0.0%)	0(0.0%)	
	Type 1	27	24(88.9%)	3(11.1%)	0(0.0%)	_
Diabetes type	Type 2	65	43(66.2%)	11(16.9%)	11(16.9%)	0.294
	LADA	3	2(66.7%)	1(33.3%)	0(0.0%)	-
	MODY	1	1(100.0%)	0(0.0%)	0(0.0%)	-
On Insulin?	No	6	4(66.7%)	2(33.3%)	0(0.0%)	0.336

	Ba	aharith and A	Alharbi, 2023				
	Pharmacophore, 14(1) 2023, Pages 100-110						
	Yes	94	70(74.5%)	13(13.8%)	11(11.7%)		
On oral hypoglycaemic	No	36	31(86.1%)	4(11.1%)	1(2.8%)	0.077	
agents?	Yes	64	43(67.2%)	11(17.2%)	10(15.6%)	0.077	
Compliant with	No	22	10(45.5%)	6(27.3%)	6(27.3%)	0.002ª	
medications?	Yes	78	64(82.1%)	9(11.5%)	5(6.4%)	0.002*	
Existing DM	No	33	28(84.8%)	5(15.2%)	0(0.0%)	0.0428	
complications?	Yes	67	46(68.7%)	10(14.9%)	11(16.4%)	- 0.042	
Comonthi divisor	None	16	14(87.5%)	2(12.5%)	0(0.0%)	0.267	
Comorbidities	Yes	84	60(71.4%)	13(15.5%)	11(13.1%)	- 0.267	
Eaurila history of dishetse	No	38	33(86.8%)	5(13.2%)	0(0.0%)	0.0168	
Family history of diabetes	Yes	62	41(66.1%)	10(16.1%)	11(17.7%)	- 0.016"	
	<sup>a</sup> -significan	t using Chi-Sq	uare Test at <0.05 l	evel.			

Participants' characteristics were tested for statistically significant relationships with exercise during the past week as illustrated in **Table 7**. However, none of the participants' characteristics seemed to be statistically significant.

**Table 7.** Statistical relationships between participants' characteristics and exercise during the past week

		<b>T</b> ( )	Exercised in tl	Exercised in the past week?		
Variab	les	Total	No	Yes	- p-value	
Total		100	79(79.0%)	21(21.0%)	-	
Age		100	$51.53 \pm 18.6$	$44.57 \pm 19.0$	0.132	
Years since d	iagnosis	99	$13.74\pm8.7$	$12.45\pm10.3$	0.564	
Combra	Male	66	50(75.8%)	16(24.2%)	0.267	
Gender	Female	34	29(85.3%)	5(14.7%)	- 0.267	
Marrital atotya	Single	22	17(77.3%)	5(22.7%)	0.822	
Marital status	Married at least once	78	62(79.5%)	16(20.5%)	- 0.822	
Educational laval	High school and below	25	22(88.0%)	3(12.0%)	0.202	
Educational level	Bachelor	75	57(76.0%)	18(24.0%)	- 0.202	
	Employed	56	42(75.0%)	14(25.0%)		
0	Housewife	9	7(77.8%)	2(22.2%)	0.591	
Occupational status	Student	9	7(77.8%)	2(22.2%)	0.581	
	Retired	26	23(88.5%)	3(11.5%)	-	
	Underweight	3	3(100.0%)	0(0.0%)		
	Normal weight	45	33(73.3%)	12(26.7%)	0.476	
BMI	Overweight	42	34(81.0%)	8(19.0%)	- 0.476	
	Obese	10	9(90.0%)	1(10.0%)	-	
	Gestational diabetes	4	2(50.0%)	2(50.0%)		
	Type 1	27	19(70.4%)	8(29.6%)	-	
Diabetes type	Type 2	65	56(86.2%)	9(13.8%)	0.054	
	LADA	3	1(33.3%)	2(66.7%)	-	
	MODY	1	1(100.0%)	0(0.0%)	='	
	No	6	6(100.0%)	0(0.0%)	0.102	
On Insulin?	Yes	94	73(77.7%)	21(22.3%)	0.193	
	No	36	25(69.4%)	11(30.6%)	0.070	
On oral hypoglycaemic agents?	Yes	64	54(84.4%)	10(15.6%)	- 0.078	
	No	22	19(86.4%)	3(13.6%)		
Compliant with medications?	Yes	78	60(76.9%)	18(23.1%)	- 0.337	
	No	33	25(75.8%)	8(24.2%)	0.57.6	
Existing DM complications?	Yes	67	54(80.6%)	13(19.4%)	- 0.576	

Pharmacophore, 14(1) 2023, Pages 100-110						
Comorbiantes —	Yes	84	68(81.0%)	16(19.0%)	0.272	
Family history of diabetes —	No	38	28(73.7%)	10(26.3%)	0 207	
	Yes	62	51(82.3%)	11(17.7%)	- 0.307	

Diabetes is a significant cause of morbidity and mortality, as well as a strain on healthcare resources, particularly in developing countries [6, 10, 18]. Using nationally representative data, this study assessed the prevalence, awareness, treatment, and glycemic control of diabetes. The literature revealed that the prevalence of diabetes and public awareness of the condition increased over time, but that despite advancements, neither medication nor glycemic control was optimum.

The literature revealed that the prevalence of diabetes has increased worldwide, including in urban and rural areas. While the worldwide average is anticipated to be 8.4% in 2017, the United States has a higher prevalence of diabetes among individuals aged 25-65 than in 2004 (8.4%) [19]. Several factors, including genetics, obesity, inactivity, urbanization, and poor eating habits, have contributed to an increased trend in recent years across the Middle East and North Africa (MENA), including Saudi Arabia [20, 21]. Consistent with the findings of this study, other national studies [22-25] have shown that the prevalence of diabetes is rising, with estimates ranging from 7.4 to 24.5%. Variations in methodology, including variances in age distribution, sample size, time, focus on the region, and lack of standard diagnostic criteria, likely contribute to inconsistencies in reported diabetes prevalence. Regardless of the approach used to evaluate the prevalence of diabetes in Saudi Arabia — self-reported data or clinical indicators such as fasting blood sugar or hemoglobin A1c — an upward trend has been seen. Due to the breadth of diabetes's potential repercussions, health policy must accord this issue significant consideration.

According to regression analyses, older individuals, women, and city inhabitants had higher diabetes rates. Similar studies [23, 26, 27] have shown that the risk of acquiring diabetes continuously increases beyond the age of 40. In addition, the incidence of gestational diabetes [28] explains why women are more likely to acquire diabetes than males, emphasizing the need of arranging high-quality prenatal care to identify and treat gestational diabetes. Several national and international research [22, 29-31] found a greater incidence of diabetes in urban regions compared to rural ones, which the literature verifies. This gap may be the result of dietary and activity variations. Even though diabetes is more prevalent in urban areas, the literature did not uncover any statistically significant differences in diabetes awareness or management between rural and urban settings. This contradicts the findings of past studies [32, 33] that indicated the growth of primary healthcare systems staffed by trained community healthcare workers enhanced disease management in rural areas.

The awareness of diabetes among diabetic patients grew from 53.5% at the beginning of the study period (2004) to 82.2% at the end of the period (2016), which is more than the estimated awareness (51% in 2017) throughout the MENA region [34]. One in two diabetics is undiagnosed, according to the International Diabetes Federation [7]. The degree of diabetes education individuals get has been proven to have a substantial link with glycemic control and the avoidance of diabetic complications [35, 36]. Multiple variables may account for the increase in awareness. The increase in public knowledge may be due, in part, to the fact that the literature indicates a rising trend in diabetes prevalence during the research period. Second, hospital-based health education and promotion activities and social media may be important factors. Last but not least, diabetes screening initiatives at PHC facilities may help spread the news. Consistent with other studies [37-39], the results of the logistic regression indicate that diabetes awareness increases with age. In accordance with earlier research [31, 39], we discovered that female participants were more likely to be aware of their diabetes risk factors and to maintain normal blood sugar levels.

While a growing trend was predicted as a consequence of publicity, the present study revealed that the proportion of individuals who had undergone treatment decreased to 39.6% by 2016. In the present study, the proportion of diabetic individuals with controlled FBS increased from 2004 to 2011 but has subsequently declined to 18.5%. During the experiment, the percentage of diabetes patients whose condition was under control increased by approximately four percent. Compared to what was projected, the percentage of patients who received medication and the percentage of patients with adequate glycemic control indicate that diabetes treatment is far from optimal [17, 40]. Multiple studies [41, 42] have questioned the efficiency of diabetes prevention and treatment activities at the system level.

Literature showed that people with health insurance were better able to spot illness signs and take preventive steps. People with health insurance are more likely to be diagnosed with diabetes than those without insurance, according to the majority of national and international research [24, 43, 44]. This is likely because insured patients have more access to healthcare than uninsured ones. Numerous studies have shown that uninsured individuals are much less likely to get routine screenings or preventive treatments [45, 46], are diagnosed with more serious diseases, and receive less therapeutic care [47]. It is good knowledge that diabetes imposes enormous financial pressures on patients, especially those with lower incomes. To improve diabetes treatment, it is essential to provide low-income individuals with financial assistance, such as increased insurance coverage and decreased copayments, particularly for drugs. In recent years, US sanctions have led to either a dearth of or astronomically high prices for essential medications like insulin, rendering them unavailable to many. Although oral pharmaceutical treatments for diabetes patients are inexpensive, the high expense of insulin therapy has been identified in prior studies [48, 49] as a critical cause of noncompliance with treatment.

Less than one-fourth of the diabetic participants in the literature attained satisfactory glycemic control. This degree of awareness is coupled with limited control. Progress in universal diabetes treatment may be gauged by whether or not type 2 diabetes is properly covered for people aged 15 and older [50]. Reaching this degree of protection requires a well-developed

## Baharith and Alharbi, 2023

#### Pharmacophore, 14(1) 2023, Pages 100-110

healthcare delivery system that can customize its services to individual needs, therefore enhancing the health of persons who get treatment [51]. Finding the core reasons for diabetes patients' poor glycemic control will need more research. It is evident, however, that the present system of care for the management of diabetes patients must be rethought to give patients with easier access to therapies of greater quality and lower cost.

## Conclusion

Participants in this study exhibited some risky behaviors with regard to their diabetes condition. Lack of exercise, smoking, less frequent blood glucose monitoring and not following up with a dietician were the most risky behaviors. This is reflected by the high prevalence of diabetes complications among study participants.

#### Acknowledgments: None

## Conflict of interest: None

## Financial support: None

**Ethics statement:** Data was stored and collected anonymously. Informed consents were signed by the patients. A conditional approval was granted by the Research and Ethics Committee, King Fahd Armed Forces Hospital.

## References

- 1. Adje UD, Ekonye KD, Oparah CA. Assessment of Diabetes Self-Care Knowledge and Satisfaction with Care among Type 2 Diabetes Patients-A Case Study. Arch Pharm Pract. 2022;13(3):23-8.
- 2. Ahmed NF, Alqahtani AS, Albalawi NM, Alanazi FK, Alharbi FM, Alsabah BA, et al. Diabetes in Adolescents and Children in Saudi Arabia: A Systematic review. Arch Pharm Pract. 2021;12(1):109-14.
- 3. Shetgaonkar KA, Suragimath G, Varma S, Zope S. Two Way Relationship between Diabetes and Periodontitis: A Cross-Sectional Survey of Knowledge, Awareness, and Attitude. Int J Pharm Res Allied Sci. 2022;11(2):1-7.
- 4. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st-century challenge. Lancet Diabetes Endocrinol. 2014;2(1):56-64.
- Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15(9):913-24.
- 6. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):1-1.
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843.
- 8. World Health Organization. Noncommunicable diseases country profiles 2018. Accessed 29 Aug 2022.
- 9. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
- Basu S, Flood D, Geldsetzer P, Theilmann M, Marcus ME, Ebert C, et al. Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model. Lancet Global Health. 2021;9(11):e1539-52.
- 11. World Health Organization. Global report on Diabetes 2020: World Health Organization; 2020.
- 12. Patcharanarumol W, Panichkriangkrai W, Wangmo S, Thammatacharee J, Uechi M, Wanwong Y. Diabetes prevention and care in the universal health coverage context: the example of Thailand. WHO Southeast Asia J Public Health. 2016;5(1):27-33.
- 13. World Health Organization. Tracking universal health coverage: first global monitoring report: World Health Organization; 2015.
- 14. World Health Organization. Tracking universal health coverage: 2017 global monitoring report: World Health Organization; 2017.
- 15. Abdi Z, Majdzadeh R, Ahmadnezhad E. Developing a framework for the monitoring and evaluation of the Health Transformation Plan in the Islamic Republic of Iran: lessons learned. East Mediterr Health J. 2019;25(6):394-405.
- Peykari N, Hashemi H, Dinarvand R, Haji-Aghajani M, Malekzadeh R, Sadrolsadat A, et al. National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. J Diabetes Metab Disord. 2017;16:1-7.
- 17. Mohseni M, Ghoreishi TS, Houshmandi S, Moosavi A, Azami-Aghdash S, Asgarlou Z. Challenges of managing diabetes in Iran: meta-synthesis of qualitative studies. BMC Health Serv Res. 2020;20(1):1-12.

#### Baharith and Alharbi, 2023

Pharmacophore, 14(1) 2023, Pages 100-110

- 18. Saadat S, Yousefifard M, Asady H, Jafari AM, Fayaz M, Hosseini M. The most important causes of death in Iranian population; a retrospective cohort study. Emergency. 2015;3(1):16.
- 19. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81.
- 20. Hwalla N, Jaafar Z, Sawaya S. Dietary management of type 2 diabetes in the MENA region: A review of the evidence. Nutrients. 2021;13(4):1060.
- 21. El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action. World J Diabetes. 2021;12(9):1401.
- 22. Khorrami Z, Yarahmadi S, Etemad K, Khodakarim S, Kameli ME, Mahdavi-Hazaveh AR. Urban-rural differences in the prevalence of self-reported diabetes and its risk factors: the WHO STEPS Iranian noncommunicable disease risk factor surveillance in 2011. Iran J Med Sci. 2017;42(5):481.
- Katibeh M, Hosseini S, Soleimanizad R, Manaviat MR, Kheiri B, Khabazkhoob M, et al. Prevalence and risk factors of diabetes mellitus in a central district in Islamic Republic of Iran: a population-based study on adults aged 40-80 years. EMHJ-East Mediterr Health J. 2015;21(6):412-9.
- 24. Mirzaei M, Rahmaninan M, Mirzaei M, Nadjarzadeh A. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. BMC Public Health. 2020;20(1):1-9.
- 25. Khamseh ME, Sepanlou SG, Hashemi-Madani N, Joukar F, Mehrparvar AH, Faramarzi E, et al. Nationwide prevalence of diabetes and prediabetes and associated risk factors among Iranian adults: analysis of data from PERSIAN cohort study. Diabetes Therapy. 2021;12:2921-38.
- 26. Lotfi MH, Saadati H, Afzali M. Prevalence of diabetes in people aged≥ 30 years: the results of screening program of Yazd Province, Iran, in 2012. J Res Health Sci. 2013;14(1):88-92.
- 27. Najafipour H, Sanjari M, Shokoohi M, Haghdoost AA, Afshari M, Shadkam M, et al. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes and its predictors in general population aged 15 to 75 years: A community-based study (KERCADRS) in southeastern Iran. J Diabetes. 2015;7(5):613-21.
- 28. Damm P, Houshmand-Oeregaard A, Kelstrup L, Lauenborg J, Mathiesen ER, Clausen TD. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia. 2016;59(7):1396-9.
- 29. Aung WP, Htet AS, Bjertness E, Stigum H, Chongsuvivatwong V, Kjøllesdal MKR. Urban–rural differences in the prevalence of diabetes mellitus among 25–74-year-old adults of the Yangon Region, Myanmar: Two cross-sectional studies. BMJ Open. 2018;8(3):e020406.
- 30. Rahman MS, Akter S, Abe SK, Islam MR, Mondal MN, Rahman JS, et al. Awareness, treatment, and control of diabetes in Bangladesh: a nationwide population-based study. PloS one. 2015;10(2):e0118365.
- 31. Supiyev A, Kossumov A, Kassenova A, Nurgozhin T, Zhumadilov Z, Peasey A, et al. Diabetes prevalence, awareness and treatment and their correlates in older persons in urban and rural population in the Astana region, Kazakhstan. Diabetes Res Clin Pract. 2016;112:6-12.
- 32. Farzadfar F, Murray CJ, Gakidou E, Bossert T, Namdaritabar H, Alikhani S, et al. Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational study. Lancet. 2012;379(9810):47-54.
- 33. Noshad S, Afarideh M, Heidari B, Mechanick JI, Esteghamati A. Diabetes care in Iran: where we stand and where we are headed. Ann Glob Health. 2015;81(6):839-50.
- 34. IDF Diabetes ATLAS: Eighth edition. 2017. Available from: https://diabetesatlas.org/upload/resources/previous/files/8/IDF\_DA\_8e-EN-final.pdf
- 35. Aswathi V, Chowta MN, Achappa B, Madi D. Correlation of awareness of the disease with glycaemic control and diabetic complications among patients attending a tertiary care hospital. Clin Diabetol. 2019;8(3):143-53.
- 36. Ozcelik F, Yiginer O, Arslan E, Serdar MA, Uz O, Kardesoglu E, et al. Association between glycemic control and the level of knowledge and disease awareness in type 2 diabetic patients. Pol Arch Med Wewn. 2010;120(10):399-406.
- 37. Safari-Faramani R, Rajati F, Tavakol K, Hamzeh B, Pasdar Y, Moradinazar M, et al. Prevalence, awareness, treatment, control, and the associated factors of diabetes in an Iranian Kurdish population. J Diabetes Res. 2019;2019.
- 38. Boo S, Yoon YJ, Oh H. Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database: A cross-sectional analysis. Medicine. 2018;97(51):e13713.
- 39. Wang C, Yu Y, Zhang X, Li Y, Kou C, Li B, et al. Awareness, treatment, control of diabetes mellitus and the risk factors: survey results from northeast China. PloS one. 2014;9(7):e103594.
- 40. Ghazizadeh-Hashemi S, Larijani B. National action plan for Prevention and Control of Non-communicable Diseases and the related risk factors in the Islamic Republic of Iran, 2015–2025. Tehran: Aftab e Andisheh Publications; 2015.
- 41. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Sci Rep. 2017;7(1):13461.
- 42. Mohammadi E, Morasa FS, Roshani S, Rezaei N, Azadnajafabad S, Moghaddam SS, et al. Estimating the attributable risk of vascular disorders in different ranges of fasting plasma glucose and assessing the effectiveness of anti-diabetes agents on risk reduction; questioning the current diagnostic criteria. J Diabetes Metab Disord. 2020;19:1423-30.

Pharmacophore, 14(1) 2023, Pages 100-110

- 43. Sosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull World Health Organ. 2009;87:512-9.
- 44. Gagliardino JJ, Chantelot JM, Domenger C, Ilkova H, Ramachandran A, Kaddaha G, et al. Diabetes education and health insurance: How they affect the quality of care provided to people with type 1 diabetes in Latin America. Data from the International Diabetes Mellitus Practices Study (IDMPS). Diabetes Res Clin Pract. 2019;147:47-54.
- 45. Ayanian JZ, Zaslavsky AM, Weissman JS, Schneider EC, Ginsburg JA. Undiagnosed hypertension and hypercholesterolemia among uninsured and insured adults in the Third National Health and Nutrition Examination Survey. Am J Public Health. 2003;93(12):2051-4.
- 46. Pagán JA, Puig A, Soldo BJ. Health insurance coverage and the use of preventive services by Mexican adults. Health Econ. 2007;16(12):1359-69.
- 47. Hadley J. Sicker and poorer—The consequences of being uninsured: A review of the research on the relationship between health insurance, medical care use, health, work, and income. Med Care Res Rev. 2003;60(2\_suppl):3S-75S.
- 48. Zarei L, Peymani P, Moradi N, Kheirandish M, Mirjalili M, Zare M. Affordability of medication therapy in diabetic patients: a scenario-based assessment in Iran's health system context. Int J Health Policy Manag. 2022;11(4):443-52.
- 49. Jalilian H, Heydari S, Mir H, Fehresti S, Hatamzadeh N, Khodayari-Zarnaq R. Forgone Care in Patients with Type 2 Diabetes: A Cross-Sectional Study. BMC Public Health. 2021;21(1):1-4.
- 50. Guerrero-Núñez S, Valenzuela-Suazo S, Cid-Henríquez P. Effective universal coverage of diabetes mellitus type 2 in Chile. Rev Lat Am Enfermagem. 2017;25:e2871.
- 51. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018;6(11):e1196-252.